An economic model to value companion diagnostics in non-small-cell lung cancer
作者： Robert D Lieberthal , Kellie Dudash , Rita Axelrod , Neil I Goldfarb
DOI: 10.2217/PME.13.7
关键词:
摘要: Aim: An economic model was used to evaluate the potential impact and cost–effectiveness of companion diagnostic testing for patients with non-small-cell lung cancer (NSCLC). Materials & methods: A decision analysis examined alternative patient management strategies advanced NSCLC who were not amenable surgical treatment. review literature provided variables develop a timely base case sensitivity analysis. future scenario also modeled. The includes three options: conventional treatment (CT), new (NT) (CD) strategy. Results: In based upon current data, cost per life-year saved CT, NT option CD US$43,367, US$47,394 US$47,779, respectively. in more expensive, effective targeted therapy US$47,748, US$69,255 US$66,369, Conclusion: s...
jefferson.edu
core.ac.uk
sci-hub.se 参考文章(20)
Joseph Ferrara, Personalized medicine: challenging pharmaceutical and diagnostic company business models. McGill Journal of Medicine. ,vol. 10, pp. 59- 61 ,(2020) , 10.26443/MJM.V10I1.619
Deborah Lubeck, Lauri S. Tock, David K. Blough, Renato G. Martins, Scott D. Ramsey, Carolina M. Reyes, Second-line and Third-line Chemotherapy for Lung Cancer: Use and Cost The American Journal of Managed Care. ,vol. 14, pp. 297- 306 ,(2008)
Stewart Bates, Progress towards personalized medicine. Drug Discovery Today. ,vol. 15, pp. 115- 120 ,(2010) , 10.1016/J.DRUDIS.2009.11.001
Nickolas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein, The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nature Biotechnology. ,vol. 24, pp. 985- 995 ,(2006) , 10.1038/NBT1234
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European Journal of Cancer. ,vol. 45, pp. 228- 247 ,(2009) , 10.1016/J.EJCA.2008.10.026
A J Atherly, D R Camidge, The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers British Journal of Cancer. ,vol. 106, pp. 1100- 1106 ,(2012) , 10.1038/BJC.2012.60
Thomas J. Smith, Bruce E. Hillner, Bending the Cost Curve in Cancer Care The New England Journal of Medicine. ,vol. 364, pp. 2060- 2065 ,(2011) , 10.1056/NEJMSB1013826
Rafael Rosell, Teresa Moran, Cristina Queralt, Rut Porta, Felipe Cardenal, Carlos Camps, Margarita Majem, Guillermo Lopez-Vivanco, Dolores Isla, Mariano Provencio, Amelia Insa, Bartomeu Massuti, Jose Luis Gonzalez-Larriba, Luis Paz-Ares, Isabel Bover, Rosario Garcia-Campelo, Miguel Angel Moreno, Silvia Catot, Christian Rolfo, Noemi Reguart, Ramon Palmero, José Miguel Sánchez, Roman Bastus, Clara Mayo, Jordi Bertran-Alamillo, Miguel Angel Molina, Jose Javier Sanchez, Miquel Taron, None, Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer The New England Journal of Medicine. ,vol. 361, pp. 958- 967 ,(2009) , 10.1056/NEJMOA0904554
J. L. Warren, K. R. Yabroff, A. Meekins, M. Topor, E. B. Lamont, M. L. Brown, Evaluation of Trends in the Cost of Initial Cancer Treatment Journal of the National Cancer Institute. ,vol. 100, pp. 888- 897 ,(2008) , 10.1093/JNCI/DJN175
Ross A. Okimoto, Brian W. Brannigan, Dennis C. Sgroi, Beth Muir, Markus J. Riemenschneider, Renee Bailey Iacona, Annetta D. Krebs, David H. Johnson, Giuseppe Giaccone, Roy S. Herbst, Christian Manegold, Masahiro Fukuoka, Mark G. Kris, José Baselga, Judith S. Ochs, Daniel A. Haber, Daphne W. Bell, Thomas J. Lynch, Sara M. Haserlat, Patricia L. Harris, Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials Journal of Clinical Oncology. ,vol. 23, pp. 8081- 8092 ,(2005) , 10.1200/JCO.2005.02.7078